| Trial ID: | L3452 |
| Source ID: | NCT01516476
|
| Associated Drug: |
Placebo
|
| Title: |
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: RO6807952|DRUG: RO6807952|DRUG: liraglutide
|
| Outcome Measures: |
Primary: Change in hemoglobin A1c (HA1c), Baseline and 12 weeks | Secondary: Change in fasting plasma glucose, Baseline and 12 weeks|Safety (incidence of adverse events), 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
2
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2011-11
|
| Completion Date: |
2012-01
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-02
|
| Locations: |
Cincinnati, Ohio, 45227, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01516476
|
